The global autoinjector market reached share of USD 2.6 Billion in 2024 and is projected to grow at a CAGR of 13.19% to reach USD 8.2 Billion by 2033. This growth is driven by rising chronic diseases, advances in biologics and biosimilars, increased preference for home healthcare, product innovations, and favorable reimbursement policies. The increasing adoption of autoinjectors for self-administration of drugs bolsters market expansion.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Autoinjector Market Key Takeaways
- Current Market Size: USD 2.6 Billion in 2024
- CAGR: 13.19% during 2025-2033
- Forecast Period: 2025-2033
- The rise in chronic diseases such as arthritis, asthma, cancer, COPD, and Alzheimer’s is a key growth driver.
- Governments promoting autoinjector use in schools and increased awareness among consumers support market growth.
- Technological advancements, patent expiry of biologics, and availability of generic autoinjectors are boosting demand.
- North America leads the market driven by a significant elderly population prone to chronic conditions.
- Challenges include high development costs of autoinjectors and competition from alternative delivery systems.
Request for a Free Sample Report:
https://www.imarcgroup.com/autoinjector-market/requestsample
Market Growth Factors
The global increase in the incidence of chronic diseases such as arthritis, asthma, cancer, chronic obstructive pulmonary disease (COPD) and Alzheimer's disease is one of the major factors responsible for the growth of the global autoinjector market as self-injecting drugs used to treat these diseases is made easy by the presence of autoinjectors. Patient convenience and efficacy of the drug administered play an important role in the market.
Government efforts to promote autoinjector use in schools influence the market. Further, increasing awareness about the benefits of autoinjectors supports their adoption among consumers. Other factors that support market growth include favorable regulations that ease approvals, increasing numbers of approvals for market access, product and technology advancements via new product innovation, patent expirations of biologics and the entry of biosimilars to the market. These factors lead to the rising adoption of autoinjector devices globally at a faster pace than before.
The anticipated growth of the biologics market can be another factor. As of 2023, the Global biologics market is USD 349.6 Billion and expected to grow at a CAGR of 7.8% to USD 699.5 Billion in 2032. Biologics receive common administration through injection. Often the administration is long-term plus frequent. Therefore, people use an autoinjector as the preferred method to administer for chronic diseases such as cancer, rheumatoid arthritis plus psoriasis. Synergies between biologic drug requirements and ease-of-use of autoinjectors present the greatest opportunities for accelerated market growth to increase patient access to advanced biologic drugs.
Market Segmentation
Breakup by Type:
- Disposable Autoinjectors
- Reusable Autoinjectors
Disposable autoinjectors hold the largest market share due to increasing incidence of chronic conditions and developments in biologic medications, facilitating safe and effective drug delivery.
Breakup by Application:
- Rheumatoid Arthritis
- Anaphylaxis
- Multiple Sclerosis
- Others
Rheumatoid arthritis represents the largest segment because patients need regular self-administered biologics injections, with autoinjectors providing convenience especially for those with reduced hand dexterity.
Breakup by End User:
- Home Care Settings
- Hospitals and Clinics
Hospitals and clinics account for the largest share driven by the preference for efficient drug delivery methods, the high frequency of patient visits for chronic disease management, and the need for precise medication administration.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America leads with the largest market share, supported by high prevalence of chronic illnesses, advanced healthcare infrastructure, substantial healthcare spending, and a strong presence of key industry players.
Regional Insights
Because of region, North America held the largest share in the autoinjectors market in 2023 and expects to maintain dominance during the forecast period, because its population of geriatric patients with chronic diseases (diabetes, multiple sclerosis, rheumatoid arthritis) increases and requires self-injection devices in the region. The North American market for autoinjectors is driven by the high degree of development, medical technology spending, and high degree of healthcare infrastructure within this region, along with its favorable reimbursement policies and varied distribution channels.
Recent Developments & News
- August 2024: Astria Therapeutics, Inc. partnered with Ypsomed for developing an autoinjector for STAR-0215.
- June 2024: The US FDA approved Pharma's tralokinumab-ldrm (Adbry) autoinjector for moderate to severe atopic dermatitis.
- June 2024: Instron launched the next generation Autoinjector Testing System compliant with ISO 11608.
Key Players
- Amgen Inc.
- Antares Pharma Inc.
- Becton Dickinson and Company
- Bristol-Myers Squibb Company
- Eisai Co. Ltd.
- Eli Lilly and Company
- Haselmeier GmbH (Sulzer Ltd.)
- Johnson & Johnson
- Mylan N.V. (Viatris Inc.)
- Novartis AG
- SHL Medical AG
- Teva Pharmaceutical Industries Ltd
- Ypsomed Holding AG
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=5436&flag=E
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-201971-6302
